Sangamo Therapeutics Inc
SGMO
Company Profile
Business description
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington’s Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
Contact
501 Canal Boulevard
RichmondCA94804
USAT: +1 510 970-6000
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
183
Stocks News & Analysis
stocks
ASX retail share remains cheap despite weaker earnings
Weaker profit result drives cut to fair value yet shares remain undervalued.
stocks
AI isn’t an economic moat killer, but it will disrupt industries
How we’re rethinking companies’ competitive advantages in an AI-first world.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,745.30 | 66.70 | 0.77% |
| CAC 40 | 7,830.18 | 86.26 | 1.11% |
| DAX 40 | 22,916.24 | 279.33 | 1.23% |
| Dow JONES (US) | 46,403.47 | 279.41 | 0.61% |
| FTSE 100 | 10,088.37 | 123.21 | 1.24% |
| HKSE | 25,335.95 | 272.24 | 1.09% |
| NASDAQ | 21,924.95 | 163.06 | 0.75% |
| Nikkei 225 | 53,749.62 | 1,497.34 | 2.87% |
| NZX 50 Index | 12,929.30 | 227.55 | 1.79% |
| S&P 500 | 6,590.44 | 34.07 | 0.52% |
| S&P/ASX 200 | 8,534.30 | 45.70 | 0.54% |
| SSE Composite Index | 3,931.84 | 50.56 | 1.30% |